Jiangsu Anbison Pharmaceutical Co., Ltd.
Form 483 issued August 18, 2023 · Taizhou, China
- Observations
- 1
- Pages
- 1
- FEI number
- 3021121841
In short: On August 18, 2023, FDA issued a Form 483 with 1 observation to Jiangsu Anbison Pharmaceutical Co., Ltd. in Taizhou, Jiangsu (FEI 3021121841). Most observations concern facilities & equipment; the most-cited regulation is 21 CFR 211.63 (equipment design, size, and location).
At a glance
1 of 1 observations on this 483 concern facilities & equipment.
Most cited: 21 CFR 211.63 (1×)
What FDA observed
Preview: the opening words of each observationDashed: section inferred by FDA Intel and checked against the regulation text
- 01
Equipment used in the manufacture, processing, packing or holding of arug products \S Not of appropriate…
This inspection in context
Questions about this 483
What did FDA find at Jiangsu Anbison Pharmaceutical Co., Ltd.?
FDA listed 1 observation on this Form 483, mostly about facilities & equipment. The most-cited regulation is 21 CFR 211.63 (equipment design, size, and location). The opening words of each observation are shown on this page.
When was Jiangsu Anbison Pharmaceutical Co., Ltd. inspected by FDA?
This Form 483 is dated August 18, 2023.
How do I get the full Form 483 for Jiangsu Anbison Pharmaceutical Co., Ltd.?
Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.